CD200 and myelodysplastic syndrome: Despite that the over-expression of CD200 has been implicated in the pathogenesis of solid tumors, hematological malignancies and its expression is indicative of poor prognosis; very few studies have investigated its accuracy in MDS patients; which substantially differ from them.